Search clinical trials for: S 95010

Total 2047 results

Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers

Cardiovascular Diseases

Belgium
Bristol-Myers Squibb

Withdrawn

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain
Celgene

Active, not recruiting

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Astrocytoma

United States, Spain
Celgene

Active, not recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Neoplasms | Lymphoma, Non-Hodgkin

France, Italy, Japan, Spain
Dana-Farber Cancer Institute
Stand Up To Cancer

Active, not recruiting

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Lymphoma | Solid Tumor, Childhood | Brain Tumor, Pediatric

United States, Canada
Shiga University
University of Chicago; Shionogi; Tokyo University; Showa University; Fukushima Medical... and other collaborators

Unknown

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
Hospira, now a wholly owned subsidiary of Pfizer
Maruishi Pharmaceutical

Completed

Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation

Sedation

Japan
Boston Scientific Corporation

Completed

Boston Scientific Post Market S-ICD Registry (EFFORTLESS)

Tachycardia, Ventricular

United Kingdom, Denmark, Italy, New Zealand, Germany, France, Netherlands, Portugal, Czechia, Spain
University Hospital, Toulouse

Completed

Combined Deep Brain Stimulation in Parkinson's Disease (SCP-FOG)

Parkinson Disease

France
Shionogi

Completed

First-in-human Study of S-588210 (S-488210+S-488211)

Head and Neck Cancer | Esophageal Cancer | Lung Cancer | Mesothelioma | Bladder Cancer

United Kingdom
The University of Texas Medical Branch, Galveston
Medicem International CR s.r.o.

Completed

Comparing Outpatient to Inpatient Cervical Ripening Using Dilapan-S® (HOMECARE)

Labor, Induced | Cervix Uteri-Diseases

United States
Kyowa Kirin Co., Ltd.

Terminated

Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Nestlé

Completed

Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas

Stool Composition

Philippines
Tomoshi Tsuchiya

Completed

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Non-small Cell Lung Cancer

Japan
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

Malaria

Mozambique
Assiut University

Unknown

Diastolic Blood Pressure and Lipid Profile in Infants (ERAhmed)

Breastfeeding, Exclusive
Shionogi

Completed

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Shionogi

Completed

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Chronic Cough

United States, United Kingdom, Japan, Ukraine, Poland, Czechia
PATH
United States Department of Defense; Johns Hopkins University Center for Immunization...

Completed

Controlled Human Infection Model Challenge/Rechallenge

Shigellosis

United States
Abbott Medical Devices

Active, not recruiting

The CONFIDENCE Registry

Severe Aortic Stenosis | Symptomatic Degenerative Aortic Stenosis

Spain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
SolAeroMed Inc.

Recruiting

Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis

Bronchiectasis | Cystic Fibrosis

Canada
Alkahest, Inc.

Completed

Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis

End-Stage Renal Disease

United States
Xuanwu Hospital, Beijing

Recruiting

Subarachnoid-Subarachnoid (S-S) Bypass Versus Adhesion Lysis in Spinal Arachnoiditis and Syringomyelia

Syringomyelia

China
ElectroCore INC

Completed

RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks

Migraine

Italy
Shionogi

Completed

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Obesity

United States
University of Aarhus
Aarhus University Hospital; Aalborg University Hospital; Qufora A/S

Completed

Examination of a New Irrigation System for Transanal Irrigation in Children With Fecal Incontinence

Fecal Incontinence | Constipation - Functional

Denmark
Rambam Health Care Campus

Unknown

Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System

Heart Failure

Israel
National Institute of Allergy and Infectious Diseases...
Gritstone bio, Inc.

Completed

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

COVID-19

United States
Shionogi

Completed

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

Atopic Dermatitis

United States
Peking University Cancer Hospital & Institute

Recruiting

Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer (RESCUE-GC)

Gastric Cancer

China
University of Oxford

Completed

Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults (RTSS)

Malaria Vaccine

Thailand
Abbott Diagnostics Division

Completed

Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol

Healthy

United States
Sun Yat-sen University

Unknown

Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer (CAPITAL)

Gastric Cancer

China
Fudan University
The First Affiliated Hospital of Anhui Medical University; Guangdong Provincial... and other collaborators

Withdrawn

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Gastric Cancer

China
Massachusetts General Hospital
American Lung Association

Recruiting

The Transitions Project: Efficacy Trial

Lung Cancer

United States
Vivacelle Bio

Not yet recruiting

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02) (VBI-S-02)

Sepsis | Septic Shock | Hypovolemia
AQTIS Medical B.V.

Enrolling by invitation

A Prospective, Multicenter, Post-marketing Clinical Follow-up Research to Evaluate the Long-term Safety of Ellansé-S Dermal Filler Made of PCL Microspheres for the Correction of Moderate-to-severe Nasolabial Folds

Moderate-to-severe Nasolabial Folds (3-4 Level of WSRS Scores) on Both Sides of the Face

China
Hospital de Clinicas de Porto Alegre

Active, not recruiting

Impact of the Placebo Effect on the Effects of Trancranial Direct Current Stimulation in Fibromyalgia

Fibromyalgia

Brazil
Shionogi

Completed

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Hepatic Impairment

United States
Shionogi

Completed

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Renal Impairment

United States
Sellas Life Sciences Group

Available

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer
TTY Biopharm
National Taiwan University Hospital; Chang Gung Memorial Hospital; Taipei Veterans... and other collaborators

Terminated

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

Pancreatic Cancer | Adjuvant Chemotherapy | Resected Pancreatic Cancer

Taiwan
Fudan University

Completed

S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukaemia (CLL) | Multiple Myeloma (MM) | B-Cell Non-Hodgkin Lymphoma (NHL)

France, Australia, Germany, Korea, Republic of, United Kingdom, Hungary, Poland, Singapore
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

France, Australia
Hoffmann-La Roche

Withdrawn

Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial

Cardiovascular Abnormalities

Canada
Prof. Dr. Helmut Hummler

Unknown

Is Synchronization More Effective During Noninvasive Ventilation in Immediately Extubated Preterm Infants? (N_SIMV)

Respiratory Distress Syndrome

Germany
Seoul National University Bundang Hospital

Unknown

S-1-induced Lacrimal Drainage Obstruction

Gastric Cancer

Korea, Republic of
Japan Clinical Cancer Research Organization
Kitasato University

Completed

Clinical Trial of Chemosensitivity Test

Gastric Cancer

Japan

Search clinical trials for: S 95010

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations